Christopher Andrew Davella

Christopher Davella practices at Penn Presbyterian Medical Center in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Christopher Davella's NPI, 1275976441, was assigned on April 8, 2013. Christopher Davella graduated from George Washington University School of Medicine in 2013. Christopher Davella holds Pennsylvania license MT203986.

Christopher Davella's primary practice is Penn Presbyterian Medical Center, at 51 North 39th Street, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-8000.

Christopher Davella's primary practice is Penn Presbyterian Medical Center in Philadelphia, Pennsylvania, part of University of Pennsylvania. Christopher Davella is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Christopher Davella to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Davella practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Christopher Davella's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Christopher Davella is licensed in Pennsylvania.

CMS data shows 552 Medicare services from Christopher Davella across 7 procedure codes in 2024, for 116 Medicare patients. Medicare paid $42,000 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 116 Medicare patients who saw Christopher Davella in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Christopher Davella's median patient age at 67, with 49% women.

In 2024, Christopher Davella wrote 330 Medicare Part D claims for 70 patients. 70% of them were for generic drugs. CMS names the drug for 167 of them, across 9 drugs with 11 or more claims each, at $911,023 in total drug cost. In 2023, CMS named 104 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Christopher Davella for performance year 2024, reported as part of a group. Christopher Davella accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Christopher Davella as offering telehealth.

CMS Open Payments shows 10 general payments to Christopher Davella from 3 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 78% of the total. Eli Lilly and Company paid the most, $295.

Christopher Davella graduated from George Washington University School of Medicine in 2013.